Mereo BioPharma Q2 FY26 net loss narrows to $7 million; R&D expenses drop to $1.81 million
Reuters2026/08/11 12:16- Mereo BioPharma posted a Q2 2026 net loss of $7.01 million, narrowing from a $14.62 million loss a year earlier.
- R&D expense fell to $1.81 million from $5.37 million, due to lower setrusumab and alvelestat program spending.
- G&A expense edged down to $5.22 million from $5.49 million, on delayed pre-commercial investment for setrusumab in Europe.
- Cash and cash equivalents declined to $30.12 million at June 30, 2026; cash runway is now expected to extend into late 2027.
- Entered an option and license deal with Sentynl for U.S. rights to alvelestat; Phase 3 is planned for early 2027 if the option is exercised.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Valued at 2 trillion! Anthropic may become the largest IPO in history, roadshow starts in October, listing before the midterm elections in November
According to sources familiar with the matter, Anthropic is expected to begin its IPO roadshow as early as mid-October and complete its listing just a few days before the U.S. midterm elections in November.
Top Investor Says XRP Is A Global Agenda. Here’s why
AI's Next Big Winners Emerging? PIMCO Avoids U.S. Stock Giants, Makes Heavy Bets on Asian "Pick-and-Shovel" Companies
PIMCO fund manager Sharef believes that as capital expenditures in AI continue to shift towards data centers and infrastructure, Asian supply chain companies—with their lower valuations and stronger profit growth—stand to benefit more directly from the AI construction cycle compared to the highly valued and increasingly indebted US tech giants. As a result, he underweights most large US tech stocks and instead is heavily invested in "picks-and-shovels" companies such as Samsung Electronics, SK Hynix, and TSMC.
Morgan Stanley lifts ADTRAN stake to 6.96% from 6.77% voting rights disclosure shows
Crypto prices
More
